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SHORT COMMUNICATION
Prediction of the clinical chemotherapeutic response of stage III lung
adenocarcinoma patients by an in vitro short term test
M. Volm1, P. Drings2, E.W. Hahn' & J. Matternt
'German Cancer Research Center, Institute ofExperimental Pathology, Im Neuenheimer Feld 280, D-6900 Heidelberg and 2Chest
Hospital, Heidelberg, Germany.
Many laboratories have attempted to develop an in vitro or
in vivo test to characterize the sensitivity or resistance of
human tumours to specific drugs for subsequent clinical use
(for review see Mattern & Volm, 1982). It appears that in
spite of apparent improvements in the methods, the
information provided by these systems remains the same:
Clinical correlations of results have shown that most tests
can determine which anticancer drugs will not be clinically
useful, but none satisfactorily predict which drugs will be
most effective (Salmon et al, 1978; Volm et al., 1979). Thus,
although some procedures have achieved clinical importance
in a few centers (e.g. Group for Sensitivity Testing of
Tumours, 1981), no single test system has acquired
widespread clinical acceptance. It is therefore not surprising
that a general disillusionment has developed in this area of
research.
However, perhaps the wrong question has been asked.
Instead of predicting which particular drugs may or may not
be effective in any individual patient it may be that the more
important question to address is: 'Which patients would
benefit from any course of chemotherapy?' Frequently,
resistant cells possess a cross-resistance to a wide range of
compounds which have no obvious structural or functional
similarities (e.g. alkaloids, anthracyclines and antibiotics).
This phenomenon has been designated as pleiotropic or
multidrug resistance (Bech-Hansen et al., 1976). With this in
mind we used in the present prospective study a simple test
in which a tumour cell suspension is prepared from the fresh
surgical specimen, treated with adriamycin and the uptake of
radioactive nucleic acid precursors is determined (Volm et
al., 1979; Volm, 1984). We investigated surgical adeno-
carcinoma specimens of the lung in stage III and compared
the test results with survival of patients treated with
chemotherapy.
Thirty-two patients with previously untreated adeno-
carcinomas of the lung in stage III (pT, pN) were included
in this investigation. The patients were operated on between
1980 and 1982. The minimum follow up time is 5 years. The
histologic classification of the tumours, based on the World
Health Organization (1981) Study, was performed by Dr
Kayser, Institute of Pathology, University of Heidelberg and
Dr Komitowski, Institute of Experimental Pathology,
German Cancer Research Center. All 32 patients had
surgical resection of the tumour (lobectomy: 15 pts;
pneumonectomy: 8 pts; thoracotomy and resection: 9 pts).
The patients were staged at the time of surgery. The
classification of the stage (pTNM) was made according to
the guidelines of the American Joint Committee for Cancer
Staging and End Results Reporting (AJC). Fourteen patients
were only treated by surgical procedures (group S=surgery
alone), 18 patients were additionally treated with cytotoxic
drugs (CT group). The chemotherapy protocols used in this
study were:
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(A) adriamycin (50mgm-2 x 1), cyclophosphamide
(1,000mg m-2 X 1), vincristine (2mgm-2 x 1), every 3
weeks, repeated up to 6 cycles.
(B) BCNU (40mgm 2 x 5), 5-fluorouracil (400mgm-2 x 5),
daily, repeated every 6 weeks for 4-6 cycles.
(C) cisplatinum (120 mgm 2 X 1), vindesine (3mgm-2 X 1)
weekly for 6 weeks, then every 2 weeks for 6 months.
Follow-up data were obtained through hospital charts and
correspondence with the patients' referring physicians.
Patients surviving less than 4 weeks after surgery were
excluded from the study (3 pts). No patients were lost to
follow-up.
Tumours of all patients were analyzed by the in vitro test.
The short term test has been described earlier (Volm et al.,
1979; Volm, 1984). Briefly, the suspensions are incubated
with adriamycin (concentration, 0.1-100pgml-1) in a water
bath for 3h. Subsequently, 3H-uridine is added during the
last hour of incubation. Aliquots of the cell suspensions are
pipetted onto filter discs, the acid-soluble radioactivity is
extracted, and the incorporated activity measured by
scintillation counting. Uptake values for the individual
concentrations are expressed as percentages of controls.
Tumours were defined as being sensitive or resistant
depending on whether uridine uptake was inhibited by more
or less than 35%, respectively (concentration of adriamycin:
10gml-1). This threshold was based on earlier studies
(Volm et al., 1979; Group for Sensitivity Testing of
Tumours, 1981).
The method for analysis of survival was the statistical
failure time model with censored data according to Kaplan
and Meier (1958). For comparison of the functions of
different populations the log-rank test and rank-sum test
were used (Gehan, 1965; Cox, 1972). Both statistical
methods are integrated in a program package of the German
Cancer Institute, Heidelberg (Edler et al., 1980).
Of the 32 patients in this study with previously untreated
adenocarcinoma of the lung in stage III, 14 were treated
with surgery alone (group S) and 18 were treated with
surgery plus chemotherapy (group CT). An analysis of the
survival times reveals that the survival curves are not
different between the S and CT groups (log-rank p=0.63,
rank-sum P=0.39, Figure la). These results are in
agreement with other reports (Legha et al., 1977; Straus et
al., 1983). However, when these same data are analyzed on
the basis of the in vitro test results (resistant, sensitive) a
different pattern emerges. As clearly evident in Figure lb the
CT patients whose tumours were sensitive in vitro lived
significantly longer than those with resistant tumours (log-
rank P=0.023, rank-sum P=0.006). The median survival
times were 185 weeks for the patients with in vitro sensitive
tumours and 31 weeks for the patients with in vitro resistant
tumours. Of importance is that there is a statistically
significant positive correlation (r=0.7) between level of
adriamycin induced inhibition of uridine uptake and patient
survival time. This means that the more sensitive the tumour
was to adriamycin the more responsive was the patient to
chemotherapy treatment. At this point it is important to
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Figure 1 Survival patterns of (a) all patients (n =32) with stage III lung adenocarcinomas subdivided according to therapy.
Fourteen patients were treated with surgery alone (group S) and 18 were treated with surgery plus chemotherapy (group CT). (b)
patients with stage III lung adenocarcinomas treated with surgery plus chemotherapy (group CT) and subdivided according to
results using the in vitro short term test (sensitive, resistant). (c) patients with stage III lung adenocarcinomas treated by surgery
alone (group S) and subdivided according to results of the in vitro short term test (sensitive and resistant).
realize that while the numbers of patients are small, the
survival times of patients who were treated with surgery
alone and divided according to the test results were not
different (log-rank P=0.14, rank-sum, P=0.24, Figure lc).
Thus the observed differences in survival times of patients
treated with surgery plus chemotherapy according to the test
results (sensitive-resistant) may be largely attributed to the
drug therapy.
The age, pT, pN, tumour size and surgery procedures were
similar in all groups (Table I). The distribution of treatment
procedures (A, B, C) is similar in both groups of patients
treated with chemotherapy. Thus, it appears that the in vitro
short term test was successful a priori in predicting which
patients might respond significantly to a chemotherapy
regimen. While we used only adriamycin to predict the
tumour response, the treatment protocols varied
considerably and therefore, further studies are required to
show whether multidrug-resistance or other reasons are
responsible for this phenomenon. Should these results be
supported by other clinical studies, it is quite possible that
more effective therapies might be designed for patients with
in vitro sensitive tumours. Similarly, those patients with in
vitro resistant tumours might be better served by entirely
new strategies, i.e. hyperthermia or immunotherapy.
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Table I Clinical characteristics within the groups of patients
pT pN Tumour Surgery CT
Number sizea
Group pts Age 2 3 0 1 2 (cm3) L P R A B C
S 14 61+ 5 1 13 6 3 5 475+ 947 5 5 4 - - -
CT 18 56+10 3 15 2 3 13 589+ 997 10 3 5 5 8 5
CTsens 8 54+ 7 1 7 0 0 8 520+ 911 4 2 2 2 4 2
CTres 10 56+ 13 2 8 2 3 5 668+1132 6 1 3 3 4 3
Ssens 5 62+ 6 0 5 1 2 2 590+1096 32- - -2
Sres 9 60+ 5 1 8 5 1 3 394+ 929 2 3 5 - -
S=surgery alone, CT=surgery plus chemotherapy, sens=sensitive, res=resistant, L=lobectomy, P
=pneumonectomy, R=resection, A,B,C=chemotherapy protocols (see text); amean+s.d.
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